Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
Bjorn EliassonÅsa EricssonAdam FridhammarAndreas NilssonSofie PerssonBarrie ChubbPublished in: PharmacoEconomics - open (2022)
ClinicalTrials.gov: NCT02863328 (PIONEER 2; registered 11 August 2016) and NCT02607865 (PIONEER 3; registered 18 November 2015).
Keyphrases